Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Cancer Research

• Publication date

  2004-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-03-1061PMID 15041722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• STEROIDRECEPTORSANDPROLIFERATIONIN THE HUMANBREAST Results and Discussion Distribution of ER in Normal Human Breast Lobules

  2006cited by this paper
• Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

  2004cited by this paper
• Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma

  2003cited by this paper
• Tamoxifen for primary breast cancer prevention in BRCA heterozygotes.

  2002cited by this paper
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

  2002cited by this paper
• Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.

  2001cited by this paper
• Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

  2001cited by this paper
• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

  2000cited by this paper
• Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases

  2000cited by this paper
• Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Hemophagocytic syndrome in five patients with Epstein–Barr virus negative B‐cell lymphoma

  1999cited by this paper
• Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

  1999cited by this paper
• Re: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

  1999cited by this paper
• Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.

  1998cited by this paper
• BRCA-associated breast cancer: absence of a characteristic immunophenotype.

  1998cited by this paper
• Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth.

  1998cited by this paper
• Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

  1998cited by this paper
• Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.

  1998cited by this paper
• The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations

  1998cited by this paper
• Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women

  1997cited by this paper
• Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.

  1997cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance.

  1988cited by this paper
• Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.

  1987cited by this paper
• Applied regression analysis 2nd ed.

  1981cited by this paper
• Applied Regression Analysis

  1968cited by this paper
• Estrogen Receptor (cid:1) Is a Novel Marker Expressed by Follicular Dendritic Cells in Lymph Nodes and Tumor-Associated Lymphoid Infiltrates

  year unknowncited by this paper

• Oncogenic activation of SMYD3-SHCBP1 promotes breast cancer development and is coupled with resistance to immune therapy

  2025cites this paper
• Alteration in estrogen receptor status in metachronous contralateral breast cancer among unilateral early breast cancer patients with BRCA 1/2 mutations.

  2025cites this paper
• The Association Between BRCA1 Expression and ER/PR Status in Breast Cancer Patients in NTB

  2025cites this paper
• NRF2 expression level and estrogen function in BRCA1-mutated breast cancer

  2025cites this paper
• Current Situation and Future Directions of Risk-reducing Salpingo-oophorectomy.

  2025cites this paper
• FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer

  2024cites this paper
• Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status

  2024cites this paper
• Effects of Endocrine Interventions Targeting ERα or PR on Breast Cancer Risk in the General Population and Carriers of BRCA1/2 Pathogenic Variants

  2024cites this paper
• Clinically Significant BRCA1 and BRCA2 Germline Variants in Breast Cancer—A Single-Center Experience

  2024cites this paper
• Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants

  2024cites this paper
• Controlled ovarian hyperstimulation in breast cancer patients: Does oestrogen receptor status make a difference?

  2023cites this paper
• Risk, molecular subtype and prognosis of second primary breast cancer: an analysis based on first primary cancers.

  2023cites this paper
• Treatment of women with BRCA mutation

  2023cites this paper
• Polygenic Risk Score Predicts Modified Risk in BRCA1 Pathogenic Variant c.4035del and c.5266dup Carriers in Breast Cancer Patients

  2023cites this paper
• Expression of BRCA1 by immunohistochemistry and its association with ER, PR, Her2neu status in infiltrative ductal carcinoma of breast

  2023cites this paper
• Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: different biological and clinical entities with potentially diverse therapeutic opportunities.

  2023cites this paper
• A Postpartum Breast Cancer Diagnosis Reduces Survival in Germline BRCA pathogenic variant Carriers

  2023cites this paper
• Polygenic risk scores and breast cancer risk prediction

  2023cites this paper
• Histological and Immunohistochemical Characteristics for Hereditary Breast Cancer Risk in a Cohort of Brazilian Women

  2022cites this paper
• High BRCA1 gene expression increases the risk of early distant metastasis in ER+ breast cancers

  2022cites this paper
• Marker assessments in ER‐positive breast cancers: old markers, new applications?

  2022cites this paper
• Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers

  2022cites this paper
• Breast Tumor Classification Based on MRI-US Images by Disentangling Modality Features

  2022cites this paper
• Breast cancer: age incidence, hormone receptor status and family history in Najaf, Iraq

  2022cites this paper
• Hormone receptor status and family history in female breast cancer

  2022cites this paper
• BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies

  2022cites this paper
• Risk‐reducing salpingo‐oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2‐mutation carriers—an Israeli matched‐pair study

  2021cites this paper
• Molecular biological subtypes of breast cancer in BRCA1 mutation carriers

  2021cites this paper
• Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers

  2021influential citation
• Prognostic Prediction of BRCA Mutations by 18F-FDG PET/CT SUVmax in Breast Cancer

  2021cites this paper
• A narrative review of biomarkers in advanced triple negative breast cancer

  2021cites this paper
• OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.

  2021cites this paper
• Survival from breast cancer in women with a BRCA2 mutation by treatment

  2021cites this paper
• Bilateral Salpingo-oophorectomy and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Assessing the Evidence

  2021cites this paper
• Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers

  2021cites this paper
• Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers

  2021cites this paper
• Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status

  2021cites this paper
• Two distinct mechanisms underlie estrogen-receptor-negative breast cancer susceptibility at the 2p23.2 locus

  2021cites this paper
• Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause

  2021cites this paper
• Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status

  2020cites this paper
• Finding the five‐year window: A qualitative study examining young women's decision‐making and experience of using tamoxifen to reduce BRCA1/2 breast cancer risk

  2020cites this paper
• Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer

  2020cites this paper
• Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which?

  2020cites this paper
• PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective

  2020cites this paper
• BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.

  2020cites this paper
• Early stage triple negative breast cancer: Management and future directions.

  2020cites this paper
• Outcomes and risk of subsequent breast events in breast‐conserving surgery patients with BRCA1 and BRCA2 mutation

  2020cites this paper
• Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?

  2020cites this paper
• Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study

  2020cites this paper
• Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients

  2020cites this paper
• Frequency of high‐risk hormone receptor‐positive breast cancer patients was much higher in Japanese breast cancer patients with germline BRCA1/2 mutations than in sporadic breast cancer patients

  2020cites this paper
• Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer.

  2020cites this paper
• Personalized early detection and prevention of breast cancer: ENVISION consensus statement

  2020cites this paper
• HRness in Breast and Ovarian Cancers

  2020cites this paper
• Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis.

  2020cites this paper
• Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China

  2019cites this paper
• Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research

  2019cites this paper
• Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review

  2019cites this paper
• BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ

  2019cites this paper
• The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability

  2019cites this paper
• A molecular basis for Estrogen Receptor- α deficiency in BRCA1-linked breast cancer

  2019cites this paper
• Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers

  2019cites this paper
• MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells

  2019cites this paper
• BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance

  2019cites this paper
• Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients

  2018cites this paper
• Invasive breast carcinomas with ATM gene variants of uncertain significance share distinct histopathologic features

  2018cites this paper
• Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?

  2018cites this paper
• BRCA1‐associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling

  2018cites this paper
• Морфологические особенности BRCA1‑ассоциированных опухолей

  2018cites this paper
• Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer

  2018cites this paper
• BRCA Mutations and Breast Cancer Prevention

  2018cites this paper
• Breast Cancer Risk Factors and Associations with Breast Cancer Tumor Characteristics in High Risk Populations

  2018cites this paper
• Population masculine au sein des familles avec mutation germinale dans les gènes BRCA1 et BRCA2 aspects cliniques et pathologiques des cancers

  2018cites this paper
• BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II–DNA complexes

  2018cites this paper
• BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1‐MCM2 signaling during pregnancy

  2018cites this paper
• DNA signatures as a predictor of breast cancer risk

  2018cites this paper
• Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis

  2018cites this paper
• Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation

  2018cites this paper
• Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer.

  2018cites this paper
• NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of BRCA1-Mutated Breast Cancer

  2017cites this paper
• Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries

  2017cites this paper
• Hereditary breast and ovarian cancer

  2017cites this paper
• Triple Negative Breast Cancer: Its Time to Kick the Can down the Road

  2017cites this paper
• Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment

  2017cites this paper
• Mammography and ultrasound effective features in differentiating basal-like and normal-like subtypes of triple negative breast cancer

  2017cites this paper
• BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays

  2017cites this paper
• Lifetime moderate-to-vigorous physical activity and ER/PR/HER-defined post-menopausal breast cancer risk

  2017cites this paper
• Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

  2017cites this paper
• The Effect of Reproductive Factors on Breast Cancer Presentation in Women Who Are BRCA Mutation Carrier

  2017cites this paper
• Environmental radon exposure and breast cancer risk in the Nurses’ Health Study II

  2017cites this paper
• A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data

  2017cites this paper
• Pathology of BRCA Tumors

  2017cites this paper
• BRCA1-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency

  2016cites this paper
• of an alveolar cell of origin to the high-grade malignant phenotype of pregnancy-associated breast cancer.

  2016cites this paper
• Young premenopausal women with breast cancer, especially estrogen receptor negative, are at significantly increased risk for subsequent ovarian cancer.

  2016cites this paper
• Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

  2016cites this paper
• Can we prevent BRCA1-associated breast cancer by RANKL inhibition?

  2016cites this paper
• Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery

  2016cites this paper
• Is estrogen receptor negative breast cancer risk associated with a fast life history strategy?

  2016cites this paper
• Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features

  2016cites this paper